Last updated: 2026-09-07 05:53:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Tiziana Life Sciences Ltd (TLSA) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.02, with a market capitalisation of $118.54M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.87 to $2.35. This page covers its latest market performance, valuation, price trends and company information.
$118.54M | |
$0.97 | |
$16.79 | |
$0.41 | |
$0.97 | |
569.92K | |
-- | |
-- | |
$2.35 | |
$0.87 | |
-- | |
-- |
Tiziana Life Sciences Ltd (TLSA) last closed at $0.97 as of 2026-09-04 23:31:00, unchanged from the previous close of $0.97.
During the latest regular trading session, TLSA traded between $0.41 and $16.79, with a volume of 569.92K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Tiziana Life Sciences Ltd (TLSA) moved from $1.02 to $1.02, representing a decline of 0.49% ($0.01).
The stock traded between $0.96 and $1.06 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 480.58 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 10.0%
TLSA is currently trading at $1.02, placing it 10.0% of the way from its 52-week low of $0.87 to its 52-week high of $2.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
| Employees | 10 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tiziana Life Sciences Ltd (TLSA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.